Skip to main content

Trade-Ideas LLC identified

ChromaDex

(

CDXC

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified ChromaDex as such a stock due to the following factors:

  • CDXC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $2.7 million.
  • CDXC has traded 978,512 shares today.
  • CDXC is trading at 38.64 times the normal volume for the stock at this time of day.
  • CDXC is trading at a new high 16.20% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CDXC with the Ticky from Trade-Ideas. See the FREE profile for CDXC NOW at Trade-Ideas

More details on CDXC:

TheStreet Recommends

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies.

The average volume for ChromaDex has been 148,300 shares per day over the past 30 days. ChromaDex has a market cap of $182.0 million and is part of the health care sector and drugs industry. The stock has a beta of 1.11 and a short float of 0.6% with 0.21 days to cover. Shares are down 22.7% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates ChromaDex as a

sell

. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

Highlights from the ratings report include:

  • Net operating cash flow has significantly decreased to -$2.90 million or 390.01% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, CHROMADEX CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • 48.35% is the gross profit margin for CHROMADEX CORP which we consider to be strong. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of 3.49% trails the industry average.
  • The debt-to-equity ratio is somewhat low, currently at 0.84, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.09, which illustrates the ability to avoid short-term cash problems.
  • This stock has increased by 35.56% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in CDXC do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.